Medical implant and methods of manufacturing the medical implant

A method of manufacturing a medical implant for occluding a left atrial appendage may include cutting an expandable scaffold in a first configuration, wherein the expandable scaffold includes a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts, forming the expandable scaffold into a second configuration, wherein forming the expandable scaffold into the second configuration includes bending each anchor member along its bending axis, the bending axis being oriented parallel to a longitudinal axis of its respective strut of the plurality of struts, and heat setting the expandable scaffold in the second configuration. The method may include securing an occlusive element to the expandable scaffold.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority of U.S. Provisional Application No. 63/350,520 filed Jun. 9, 2022, the entire disclosure of which is hereby incorporated by reference.

TECHNICAL FIELD

The present disclosure pertains to medical devices and systems, and methods for manufacturing and using medical devices and systems. More particularly, the present disclosure pertains to medical implants for occluding a left atrial appendage and methods of manufacturing the medical implants.

BACKGROUND

Diseases and/or medical conditions that impact the cardiovascular system are prevalent throughout the world. Traditionally, treatment of the cardiovascular system was often conducted by directly accessing the impacted part of the system. More recently, less invasive therapies have been developed, and have gained wide acceptance among patients and clinicians.

Atrial fibrillation a common sustained cardiac arrhythmia affecting over 30 million people worldwide, according to some estimates. Atrial fibrillation is the irregular, chaotic beating of the upper chambers of the heart. Electrical impulses discharge so rapidly that the atrial muscle quivers or fibrillates. Episodes of atrial fibrillation may last a few minutes or several days. The most serious consequence of atrial fibrillation is ischemic stroke. It has been estimated that up to 20% of all strokes are related to atrial fibrillation. Most atrial fibrillation patients, regardless of the severity of their symptoms or frequency of episodes, require treatment to reduce the risk of stroke. The left atrial appendage is a small organ attached to the left atrium of the heart as a pouch-like extension. In patients suffering from atrial fibrillation, the left atrial appendage may not properly contract with the left atrium, causing stagnant blood to pool within its interior, which can lead to the undesirable formation of thrombi within the left atrial appendage. Thrombi forming in the left atrial appendage may break loose from this area and enter the blood stream. Thrombi that migrate through the blood vessels may eventually plug a smaller vessel downstream and thereby contribute to stroke or heart attack. Clinical studies have shown that the majority of blood clots in patients with atrial fibrillation are found in the left atrial appendage. As a treatment, medical devices have been developed which are positioned in the left atrial appendage and deployed to close off the ostium of the left atrial appendage. Over time, the exposed surface(s) spanning the ostium of the left atrial appendage becomes covered with tissue (a process called endothelization), effectively removing the left atrial appendage from the circulatory system and reducing or eliminating the number of thrombi which may enter the blood stream from the left atrial appendage.

The disclosure relates to medical implants for occluding the left atrial appendage and/or methods of manufacturing the medical implants. Of the known medical devices, systems, and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices and systems, as well as alternative methods for manufacturing and using medical devices and systems.

SUMMARY

In one example, a method of manufacturing a medical implant for occluding a left atrial appendage may comprise cutting an expandable scaffold in a first configuration, wherein the expandable scaffold includes a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts; forming the expandable scaffold into a second configuration, wherein forming the expandable scaffold into the second configuration includes bending each anchor member along its bending axis, the bending axis being oriented parallel to a longitudinal axis of its respective strut of the plurality of struts; and heat setting the expandable scaffold in the second configuration.

In additional or alternatively to any example described herein, the expandable scaffold is cut with a laser.

In additional or alternatively to any example described herein, the first configuration is a radially collapsed configuration and the second configuration is a radially expanded configuration.

In additional or alternatively to any example described herein, each anchor member extends radially outward from the plurality of struts after bending.

In additional or alternatively to any example described herein, forming the expandable scaffold into the second configuration includes preventing the plurality of struts from twisting.

In additional or alternatively to any example described herein, bending each anchor member includes preventing its respective strut from rotating about the longitudinal axis of the respective strut as the anchor member is bent.

In additional or alternatively to any example described herein, the expandable scaffold is formed from a unitary tubular member.

In additional or alternatively to any example described herein, bending each anchor member includes inserting a punch into an interior of the expandable scaffold, and moving the punch radially outward relative to the plurality of struts.

In additional or alternatively to any example described herein, moving the punch radially outward relative to the plurality of struts simultaneously bends more than one of the plurality of anchor members.

In additional or alternatively to any example described herein, bending each anchor member includes inserting a die into an interior of the expandable scaffold, positioning its respective strut over a groove formed in the die, and urging the respective strut into the groove with a punch.

In additional or alternatively to any example described herein, the expandable scaffold is formed from a flat sheet of material.

In additional or alternatively to any example described herein, bending each anchor member includes moving a punch through the expandable scaffold without moving the plurality of struts.

In additional or alternatively to any example described herein, bending each anchor member includes positioning its respective strut over a groove formed in a die, and urging the respective strut into the groove with a punch.

In additional or alternatively to any example described herein, the method may further comprise forming the flat sheet of material into a tubular member.

In additional or alternatively to any example described herein, a method of manufacturing a medical implant for occluding a left atrial appendage may comprise cutting an expandable scaffold in a first configuration, wherein the expandable scaffold includes a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts; forming the expandable scaffold into a second configuration, wherein forming the expandable scaffold into the second configuration includes bending each anchor member along its bending axis, the bending axis being oriented parallel to a longitudinal axis of its respective strut of the plurality of struts; heat setting the expandable scaffold in the second configuration; and securing an occlusive element to the expandable scaffold.

In additional or alternatively to any example described herein, at least some of the plurality of anchor members extend through the occlusive element in the second configuration.

In additional or alternatively to any example described herein, the occlusive element is disposed along an exterior surface of the expandable scaffold.

In additional or alternatively to any example described herein, the occlusive element covers at least 30% of the expandable scaffold in the second configuration.

In additional or alternatively to any example described herein, a medical implant for occluding a left atrial appendage may comprise an expandable scaffold configured to shift from a radially collapsed configuration to a radially expanded configuration. The expandable scaffold may include a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts. In the radially expanded configuration, each anchor member may have a bending axis oriented parallel to a longitudinal axis of its respective strut of the plurality of struts and each anchor member, and the plurality of anchor members may extend radially outward from the plurality of struts.

In additional or alternatively to any example described herein, each bending axis is oriented parallel to a central longitudinal axis of the expandable scaffold in the radially collapsed configuration.

The above summary of some embodiments, aspects, and/or examples is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The figures and detailed description which follow more particularly exemplify these embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:

FIGS. 1-2 are side views of an example medical device system;

FIG. 3 is a side view of a prior art configuration of a medical implant;

FIG. 4 illustrates a flat pattern of an expandable scaffold of the medical implant of FIG. 3;

FIG. 5 is a detailed view of a portion of the flat pattern of FIG. 4;

FIG. 6 is a perspective view of a portion of a flat pattern of an expandable scaffold according to the disclosure;

FIGS. 7-8 illustrates selected aspects of a method of manufacturing the expandable scaffold of FIG. 6;

FIG. 9 illustrates selected aspects of the expandable scaffold of FIG. 6 after forming anchor members;

FIGS. 10-10A illustrate selected aspects of an alternative configuration of the expandable scaffold of FIG. 9;

FIG. 11 is a perspective view of a portion of a flat pattern of an expandable scaffold according to the disclosure;

FIGS. 12-14 illustrates selected aspects of a method of manufacturing the expandable scaffold of FIG. 11; and

FIG. 15 illustrates selected aspects of the expandable scaffold of FIG. 11 after forming anchor members.

While aspects of the disclosure are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DETAILED DESCRIPTION

The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the disclosure. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate exemplary aspects of the disclosure.

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.

All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.

The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

Although some suitable dimensions, ranges, and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges, and/or values may deviate from those expressly disclosed.

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. For simplicity and clarity purposes, all elements of the disclosure are not necessarily shown in each figure or discussed in detail below. However, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one, unless explicitly stated to the contrary.

Relative terms such as “proximal”, “distal”, “advance”, “retract”, variants thereof, and the like, may be generally considered with respect to the positioning, direction, and/or operation of various elements relative to a user/operator/manipulator of the device, wherein “proximal” and “retract” indicate or refer to closer to or toward the user and “distal” and “advance” indicate or refer to farther from or away from the user. In some instances, the terms “proximal” and “distal” may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan. Other relative terms, such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device. Still other relative terms, such as “axial”, “circumferential”, “longitudinal”, “lateral”, “radial”, etc. and/or variants thereof generally refer to direction and/or orientation relative to a central longitudinal axis of the disclosed structure or device.

The term “extent” may be understood to mean the greatest measurement of a stated or identified dimension, unless the extent or dimension in question is preceded by or identified as a “minimum”, which may be understood to mean the smallest measurement of the stated or identified dimension. For example, “outer extent” may be understood to mean a maximum outer dimension, “radial extent” may be understood to mean a maximum radial dimension, “longitudinal extent” may be understood to mean a maximum longitudinal dimension, etc. Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage. Generally, an “extent” may be considered the greatest dimension measured according to the intended usage, while a “minimum extent” may be considered the smallest dimension measured according to the intended usage. In some instances, an “extent” may be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.

The terms “monolithic” and “unitary” shall generally refer to an element or elements made from or consisting of a single structure or base unit/element. A monolithic and/or unitary element shall exclude structure and/or features made by assembling or otherwise joining multiple discrete structures or elements together.

It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to use the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or arrangeable with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.

For the purpose of clarity, certain identifying numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the description and/or claims to name and/or differentiate between various described and/or claimed features. It is to be understood that the numerical nomenclature is not intended to be limiting and is exemplary only. In some embodiments, alterations of and deviations from previously used numerical nomenclature may be made in the interest of brevity and clarity. That is, a feature identified as a “first” element may later be referred to as a “second” element, a “third” element, etc. or may be omitted entirely, and/or a different feature may be referred to as the “first” element. The meaning and/or designation in each instance will be apparent to the skilled practitioner.

The figures illustrate selected components and/or arrangements of medical implants, systems, and methods of manufacturing the same. It should be noted that in any given figure, some features of the medical implants, systems, and methods may not be shown, or may be shown schematically, for simplicity. Additional details regarding some elements may be illustrated in other figures in greater detail. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. As such, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one within the medical implants, systems, and methods of manufacturing, unless explicitly stated to the contrary. The devices and/or methods disclosed herein may provide a number of desirable features and benefits as described in more detail below.

FIG. 1 schematically illustrates selected components and/or arrangements of a medical device system 10. The medical device system 10 may be used to deliver and/or deploy a variety of medical implants (e.g., a cardiovascular medical implant, an occlusive medical implant, a replacement heart valve implant, etc.) to one or more locations within the anatomy, including but not limited to, in some embodiments, the heart. In some embodiments, the medical device system 10 may include a delivery device that can be used for percutaneous delivery of a replacement heart valve implant (e.g., a replacement mitral valve, a replacement aortic valve, etc.) to an area of interest in the anatomy, such as a native heart valve. This, however, is not intended to be limiting as the medical device system 10 and/or the delivery device may also be used for other interventions including valve repair, valvuloplasty, and the like, or other similar interventions.

The medical device system 10 including a catheter 40 having a lumen 42 extending from a proximal opening to a distal opening, a core wire 30 slidably disposed within the lumen 42, and a medical implant 100 (e.g., a cardiovascular medical implant, an occlusive medical implant, etc.) having an expandable scaffold configure to shift between a first configuration (e.g., FIG. 1), wherein the medical implant 100 is disposed within the lumen 42 proximate the distal opening in the first configuration, and a second configuration (e.g., FIG. 2), wherein the medical implant 100 and/or the expandable scaffold is configured to shift between the first configuration and the second configuration when the medical implant 100 is disposed distal of the distal opening of the lumen 42 and/or the catheter 40, and/or when the medical implant 100 is unconstrained by the catheter 40. The medical implant 100 may be disposed at and/or releasably connected to a distal portion of the core wire 30. The core wire 30 may be slidably and/or rotatably disposed within the lumen 42 of the catheter 40. In some embodiments, a proximal end of the core wire 30 may extend proximally of a proximal end of the catheter 40 and/or the proximal opening of the lumen 42 for manual manipulation by a clinician or practitioner. In some embodiments, the example medical implant 100 may be removably attached, joined, or otherwise connected to the distal end of the core wire 30. Some suitable, but non-limiting, examples of materials for the medical device system 10, the core wire 30, the catheter 40, and/or the medical implant 100, etc. are discussed below. It is contemplated that any and/or all example occlusive implants disclosed herein may be used in accordance with and/or be associated with the example medical device system 10 described above.

FIG. 3 illustrates selected aspects of the medical implant 100. The medical implant 100 includes an expandable scaffold 110 configured to shift between the first configuration (e.g., FIG. 1) and the second configuration (e.g., FIGS. 2-3). The first configuration may be a radially collapsed configuration and the second configuration may be a radially expanded configuration. The expandable scaffold 110 may have a central longitudinal axis 111. A proximal end 114 of the expandable scaffold 110 may be configured to releasably attach or connect to the distal end of the core wire 30. The proximal end 114 of the expandable scaffold 110 includes a threaded insert configured to engage a threaded member disposed at the distal end of the core wire 30. The expandable scaffold 110 includes a plurality of anchor members 112 each connected to the expandable scaffold 110 at an intersection point 116 between adjacent struts of the expandable scaffold 110. The expandable scaffold 110 includes a plurality of struts, wherein ends of adjacent struts of the plurality of struts are joined together, connected, etc. at the intersection point(s) 116. The free end 118 of the plurality of anchor members 112 extends radially outward from the expandable scaffold 110 in the second configuration. The plurality of anchor members 112 is configured to engage a wall of a left atrial appendage in the second configuration. The medical implant 100 includes an occlusive element 120 coupled to the expandable scaffold 110.

A method of manufacturing the medical implant 100 may include forming and/or cutting the expandable scaffold 110 from a unitary tubular member in the first configuration. Alternatively, the method of manufacturing the medical implant 100 may include forming and/or cutting the expandable scaffold 110 from a flat sheet of material that is later rolled and/or formed into a tubular member. After forming the flat sheet of material into a tubular member, the tubular member may be welded or otherwise fixedly secured into a tubular shape. After cutting the expandable scaffold 110, the method may include forming the expandable scaffold 110 into the second configuration. As part of forming the expandable scaffold 110 into the second configuration, the method may include bending each anchor member of the plurality of anchor members 112. After forming the expandable scaffold 110 into the second configuration, the method may include heat setting the expandable scaffold 110 in the second configuration.

FIG. 4 is a flat pattern view of the expandable scaffold 110 of FIG. 3, and FIG. 5 is a detailed view of a portion of FIG. 4. The flat pattern view is used herein to improve clarity of the disclosure. However, it shall be understood that in some embodiments, forming and/or cutting the expandable scaffold from a unitary tubular member may be preferred and illustration of a flat pattern does not constitute a preference for forming and/or cutting the expandable scaffold from a flat sheet of material.

As illustrated, the expandable scaffold 110 includes the plurality of anchor members 112 connected to the expandable scaffold 110 at the intersection point(s) 116. Each anchor member of the plurality of anchor members 112 includes a free end 118 extending away from the intersection point 116. The plurality of anchor members 112 are oriented substantially parallel to the struts of the expandable scaffold 110 in the first configuration. As part of forming the expandable scaffold 110 into the second configuration, the method includes bending the free end 118 away from the expandable scaffold 110 around a bending axis to the orientation shown in FIG. 3. Each anchor member of the plurality of anchor members 112 extends radially outward from the plurality of struts after bending. The bending axis of each anchor member is oriented transverse or perpendicular to the central longitudinal axis 111 of the expandable scaffold 110 and/or the bending axis is oriented transverse or perpendicular to a longitudinal axis of the struts of the expandable scaffold 110 in the first configuration. The bending axis may be askew from the central longitudinal axis 111 of the expandable scaffold 110 (e.g., the bending axis does not intersect the central longitudinal axis 111). Existing configurations and/or methods may require the plurality of anchor members 112 to each be formed and/or bent individually (e.g., one at a time).

The process of bending the free end(s) 118 of the plurality of anchor members 112 includes and/or introduces significant variability in the height 119 of the anchor members, shown in FIG. 3, as well as the angle of the free end 118 relative to the central longitudinal axis 111 of the expandable scaffold 110 and/or relative to the adjacent struts of the expandable scaffold 110. For proper anchoring after deployment, several manufacturing specifications must be maintained within design tolerances. The manufacturing specifications may include height, angle, radius, skew, etc. The complexity and difficulty associated with the bending process of forming the plurality of anchor members 112, as well as the quantity of anchor members, produce opportunities for the expandable scaffold 110 to be out of specification. For example, the free end 118 may experience spring back after bending. Spring back is a normal byproduct of the bending process and may affect at least the height and/or the angle of the anchor member. Spring back may be at least partially compensated for but can sometimes be unpredictable and/or inconsistent. Disclosed herein are methods and/or configurations that may significantly reduce variation within the expandable scaffold 110, thereby reducing scrap rates, reducing manufacturing costs, and/or improving quality.

FIG. 6 illustrates a detailed view of a portion of a flat pattern of an alternative configuration for the expandable scaffold 110 that is intended to remedy at least some of the difficulties that arise when bending the plurality of anchor members 112 of FIGS. 3-5. As shown in FIG. 6, the expandable scaffold 110 may include a plurality of struts 130 oriented generally parallel to each other and/or the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration. Each strut of the plurality of struts 130 may include and/or have a longitudinal axis 132 oriented generally parallel to the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration.

The expandable scaffold 110 may include a plurality of anchor members 140 each extending laterally and/or circumferentially from a medial portion of a strut of the plurality of struts 130 of the expandable scaffold 110. Each anchor member of the plurality of anchor members 140 may include a first end fixedly attached to and/or integrally formed with the medial portion of the strut and a free end 142 opposite the first end. In some embodiments, each anchor member may extend in a distal direction from the first end and the free end 142 of each anchor member may be formed into a hook shape having a tip extending in a proximal direction.

In some embodiments, the plurality of struts 130 may be longitudinally discontinuous (e.g., the struts do not extend in a straight line between ends). In some embodiments, at least some struts of the plurality of struts 130 may each include an offset portion 134 and/or a support portion 136 longitudinally offset from and/or longitudinally spaced apart from the offset portion 134. In some embodiments, the offset portion 134 and/or the support portion 136 may be laterally and/or circumferentially offset from the longitudinal axis 132 of the strut. In some embodiments, the offset portion 134 and/or the support portion 136 may extend laterally and/or circumferentially from the strut and/or the longitudinal axis 132 of the strut.

In some embodiments, the free end 142 of each anchor member of the plurality of anchor members 140 may extend laterally and/or circumferentially across the longitudinal axis 132 of an adjacent strut of the plurality of struts 130 in the first configuration. In some embodiments, the offset portion 134 may extend around the free end 142 of the anchor member of an adjacent strut of the plurality of struts 130. In some embodiments, each support portion 136 may be disposed laterally and/or circumferentially opposite the first end of one anchor member of the plurality of anchor members 140 relative to the longitudinal axis 132 of the strut.

A method of manufacturing the medical implant 100 may include cutting the expandable scaffold 110 in the first configuration, as discussed herein, to produce the configuration shown in FIG. 6 for example. In some embodiments, the expandable scaffold 110 may be cut with a laser. In some embodiments, the expandable scaffold 110 may be cut with a waterjet. In some embodiments, the expandable scaffold 110 may be machined. Other manufacturing methods and/or processes are also contemplated.

In some embodiments, the method may include forming the expandable scaffold 110 into the second configuration, as at least partially shown in FIGS. 7-8. In some embodiments, forming the expandable scaffold 110 into the second configuration may include restraining the expandable scaffold 110 and/or the plurality of struts 130. In some embodiments, restraining the expandable scaffold 110 and/or the plurality of struts 130 may include grasping and/or pinching at least some of the plurality of struts 130. In some embodiments, restraining the expandable scaffold 110 and/or the plurality of struts 130 may include pressing at least one restraining plate 150 against the expandable scaffold 110 and/or the plurality of struts 130, as shown in FIG. 7. In some embodiments, restraining the expandable scaffold 110 and/or the plurality of struts 130 may include pressing at least one restraining plate 150 against the offset portion 134 and/or the support portion 136. In some embodiments, the expandable scaffold 110, the plurality of struts 130, the offset portion 134, and/or the support portion 136 may be secured against a die, a base plate, or some other suitable structure by the at least one restraining plate 150. The at least one restraining plate 150 may include cutouts 152 that generally align with the offset portion 134 of the plurality of struts 130.

In some embodiments, forming the expandable scaffold 110 into the second configuration may include bending each anchor member along its bending axis. The bending axis may be oriented generally parallel to the longitudinal axis 132 of its respective strut of the plurality of struts 130 in the first configuration. In some embodiments, bending each anchor member along its bending axis may orient at least a portion of the anchor member at about 90 degrees relative to its respective strut in the second configuration. In some embodiments, bending each anchor member along its bending axis may orient the entire anchor member at about 90 degrees relative to its respective strut in the second configuration.

In some embodiments, the expandable scaffold 110 may be formed from a unitary tubular member. In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include inserting a punch 160 into an interior of the expandable scaffold 110, which may be understood to be below the expandable scaffold 110 in the views shown in FIGS. 7-8, and moving the punch radially outward relative to the plurality of struts 130, as shown in FIG. 8. The cutouts 152 in the at least one restraining plate 150 may permit the free end 142 of the plurality of anchor members 140 to pass through the at least one restraining plate 150 as the plurality of anchor members 140 is bent. Each anchor member may extend radially outward from the plurality of struts 130 after bending and/or in the second configuration. In some embodiments, moving the punch 160 radially outward relative to the plurality of struts 130 may simultaneously bend more than one of the plurality of anchor members 140. This may reduce the number of bending operations required to form the expandable scaffold 110 into the second configuration, thereby improving manufacturing efficiency and/or cost.

In some embodiments, the expandable scaffold 110 may be formed from a flat sheet of material. In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include moving a punch 160 through the expandable scaffold 110 without moving the plurality of struts 130, as shown in FIG. 8. The cutouts 152 in the at least one restraining plate 150 may permit the free end 142 of the plurality of anchor members 140 to pass through the at least one restraining plate 150 as the plurality of anchor members 140 is bent. In some embodiments, moving the punch 160 through the expandable scaffold 110 may simultaneously bend more than one of the plurality of anchor members 140. This may reduce the number of bending operations required to form the expandable scaffold 110 into the second configuration, thereby improving manufacturing efficiency and/or cost. The method may further comprise forming the flat sheet of material into a tubular member such that each anchor member extends radially outward from the plurality of struts 130 in the second configuration.

In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include preventing the plurality of struts 130 from twisting. As seen in FIG. 9, none of the plurality of struts 130 are twisted after the plurality of anchor members 140 is bent. In some embodiments, bending each anchor member may include preventing its respective strut from rotating about the longitudinal axis 132 of the respective strut as the anchor member is bent. In at least some embodiments, restraining the plurality of struts 130, the offset portion 134, and/or the support portion 136 with the at least one restraining plate 150 may prevent the plurality of struts 130 from twisting and/or rotating about the longitudinal axis 132 as the punch 160 is moved through the expandable scaffold 110 and/or as the punch 160 is moved radially outward relative to the plurality of struts 130, thereby bending each anchor member it contacts along its bending axis. In some embodiments, each anchor member may be bent about and/or along an edge of the at least one restraining plate 150. The bending axis of each anchor member may be oriented generally parallel to the longitudinal axis 132 of each anchor member's respective strut of the plurality of struts 130 in the first configuration. The bending axis may be oriented generally parallel to the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration. In at least some embodiments, the bending axis may be oriented along and/or may be coincident with the edge of the at least one restraining plate 150. In some embodiments, the bending axis may be disposed along and/or immediately adjacent to an edge of each anchor member's respective strut. In some embodiments, the bending axis may be disposed at and/or immediately adjacent to the first end of each anchor member.

FIG. 10 is a perspective view illustrating an alternative configuration for the plurality of anchor members 140 extending laterally and/or circumferentially from the medial portion of a strut of the plurality of struts 130 of the expandable scaffold 110. FIG. 10A is an end view of the alternative configuration of FIG. 10. Similar to the plurality of anchor members 140 discussed with respect to FIGS. 6-9 above, each anchor member may be bent along its bending axis. In at least some embodiments, the bending axis may be oriented generally parallel to the longitudinal axis 132 of each anchor member's respective strut of the plurality of struts 130. In some embodiments, the bending axis may be spaced apart from each anchor member's respective strut such that the anchor member is bent along a body portion 144 of the anchor member at a location between the first end and the free end 142, thereby orienting at least a portion of the anchor member at about 90 degrees relative to its respective strut in the second configuration.

FIGS. 11-15 illustrate selected aspects of a method of manufacturing an alternative configuration for the expandable scaffold 110. FIG. 11 illustrates a detailed view of a portion of a flat pattern of the alternative configuration for the expandable scaffold 110 that is intended to remedy at least some of the difficulties that arise when bending the plurality of anchor members 112 of FIGS. 3-5. As shown in FIG. 11, the expandable scaffold 110 may include a plurality of struts 230 oriented generally parallel to each other and/or the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration. Each strut of the plurality of struts 230 may include and/or have a longitudinal axis 232 oriented generally parallel to the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration.

The expandable scaffold 110 may include a plurality of anchor members 240 each extending laterally and/or circumferentially from a medial portion of a strut of the plurality of struts 230 of the expandable scaffold 110. Each anchor member of the plurality of anchor members 240 may include a first end fixedly attached to and/or integrally formed with the medial portion of the strut and a free end 242 opposite the first end. In some embodiments, each anchor member may extend in a distal direction from the first end and the free end 242 of each anchor member may be formed into a hook shape having a tip extending in a proximal direction. In some embodiments, the plurality of struts 230 may be longitudinally continuous (e.g., the struts extend in a straight line between ends). Anchor members on adjacent struts of the plurality of struts 230 may be longitudinally offset and/or longitudinally spaced apart from each other. In some embodiments, each strut of the plurality of struts 230 may include a pair of anchor members of the plurality of anchor members 240 extending from opposite sides of the strut at a common axial location along the strut. In some embodiments, each strut of the plurality of struts 230 may include multiple pairs of anchor members of the plurality of anchor members 240, wherein each pair extends from opposite sides of the strut at its own common axial location along the strut (e.g., a first pair extends from opposite sides of the strut at a first location, a second pair extends from opposite sides of the strut at a second location, etc.).

A method of manufacturing the medical implant 100 may include cutting the expandable scaffold 110 in the first configuration, as discussed herein, to produce the configuration shown in FIG. 11 for example. In some embodiments, the expandable scaffold 110 may be cut with a laser. In some embodiments, the expandable scaffold 110 may be cut with a waterjet. In some embodiments, the expandable scaffold 110 may be machined. Other manufacturing methods and/or processes are also contemplated.

In some embodiments, forming the expandable scaffold 110 into the second configuration may include bending each anchor member along its bending axis. The process of bending each anchor member along its bending axis is illustrated in FIGS. 12-15 using a single strut of the plurality of struts 230, wherein FIG. 15 illustrates the plurality of anchor members 240 after bending and/or in the second configuration. In some embodiments, multiple struts of the plurality of struts 230 may be processed at one time, simultaneously, etc. In some embodiments, each strut of the plurality of struts 230 may be processed one at a time, sequentially, etc. The bending axis may be oriented generally parallel to the longitudinal axis 232 of its respective strut of the plurality of struts 230 in the first configuration. In some embodiments, bending each anchor member along its bending axis may orient at least a portion of the anchor member at about 90 degrees relative to its respective strut in the second configuration. In some embodiments, bending each anchor member along its bending axis may orient the free end 242 of the anchor member at about 90 degrees relative to its respective strut in the second configuration.

In some embodiments, the expandable scaffold 110 may be formed from a unitary tubular member. In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include inserting a die 250 into an interior of the expandable scaffold 110, which may be understood to be below the expandable scaffold 110 in the views shown in FIGS. 12-14. Bending each anchor member may include positioning its respective strut of the plurality of struts 230 over a groove 252 formed in the die 250, as seen in FIG. 12. Bending each anchor member may include urging, pushing, forcing, moving, etc. the respective strut of the plurality of struts 230 into the groove 252 of the die 250 with a punch 260, as seen in FIG. 13. In some embodiments, the punch 260 may be moved radially inward toward the die 250. In some embodiments, the die 250 may be moved radially outward toward the punch 260. The respective strut of the plurality of struts 230 may be squeezed, pinched, clamped, etc. between the punch 260 and the die 250. Each anchor member may extend radially outward from the plurality of struts 230 after bending and/or in the second configuration. In some embodiments, urging, pushing, forcing, moving, etc. the respective strut of the plurality of struts 230 into the groove 252 of the die 250 with the punch 260 may simultaneously bend more than one of the plurality of anchor members 240. This may reduce the number of bending operations required to form the expandable scaffold 110 into the second configuration, thereby improving manufacturing efficiency and/or cost.

In some embodiments, the expandable scaffold 110 may be formed from a flat sheet of material. In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include positioning its respective strut of the plurality of struts 230 over the groove 252 formed in the die 250, as seen in FIG. 12. In some embodiments, the longitudinal axis 232 of the respective strut of the plurality of struts 230 may be aligned with and/or parallel to the groove 252 formed in the die 250. Bending each anchor member may include urging, pushing, forcing, moving, etc. the respective strut of the plurality of struts 230 into the groove 252 of the die 250 with the punch 260, as seen in FIG. 13. In some embodiments, the punch 260 may be moved toward the die 250. In some embodiments, the die 250 may be moved toward the punch 260. The respective strut of the plurality of struts 230 may be squeezed, pinched, clamped, etc. between the punch 260 and the die 250. In some embodiments, urging, pushing, forcing, moving, etc. the respective strut of the plurality of struts 230 into the groove 252 of the die 250 with the punch 260 may simultaneously bend more than one of the plurality of anchor members 240. This may reduce the number of bending operations required to form the expandable scaffold 110 into the second configuration, thereby improving manufacturing efficiency and/or cost. The method may further comprise forming the flat sheet of material into a tubular member such that each anchor member extends radially outward from the plurality of struts 230 in the second configuration.

In some embodiments, forming the expandable scaffold 110 into the second configuration and/or bending each anchor member may include preventing the plurality of struts 230 from twisting. As seen in FIGS. 14-15, the plurality of struts 230 is not twisted after the plurality of anchor members 240 is bent. In some embodiments, bending each anchor member may include preventing its respective strut from rotating about the longitudinal axis 232 of the respective strut as the anchor member is bent. In at least some embodiments, squeezing, pinching, clamping, etc. the plurality of struts 230 between the punch 260 and the die 250 may prevent the plurality of struts 230 from twisting and/or rotating about the longitudinal axis 232 as the punch 260 is moved toward the die 250, thereby bending each anchor member it contacts along its bending axis. In some embodiments, each anchor member may be bent about and/or along an edge of the punch 260. The bending axis of each anchor member may be oriented generally parallel to the longitudinal axis 232 of each anchor member's respective strut of the plurality of struts 230 in the first configuration. The bending axis may be oriented generally parallel to the central longitudinal axis 111 of the expandable scaffold 110 in the first configuration. In at least some embodiments, the bending axis may be oriented along and/or may be coincident with the edge of the punch 260. In some embodiments, the bending axis may be disposed along and/or adjacent to an edge of each anchor member's respective strut. In some embodiments, the bending axis may be disposed at and/or immediately adjacent to the first end of each anchor member.

In some embodiments, the method of manufacturing the medical implant 100 may include heat setting the expandable scaffold 110 and/or the plurality of anchor members 240 in the second configuration. In some embodiments, the method of manufacturing the medical implant 100 may include heat setting the expandable scaffold 110 and/or the plurality of anchor members 240 in the second configuration after bending the plurality of anchor members 240 radially outward from the plurality of struts 230. In some embodiments, the method of manufacturing the medical implant 100 may include heat setting at least some of the plurality of anchor members 240 after bending some of the plurality of anchor members 240 radially outward from the plurality of struts 230 and before all of the plurality of anchor members 240 have been bent radially outward from the plurality of struts 230. In some embodiments, the method of manufacturing the medical implant 100 may include heat setting the expandable scaffold 110 and/or the plurality of anchor members 240 in the second configuration after bending all of the plurality of anchor members 240 radially outward from the plurality of struts 230. Other configurations and/or orders of operations are also contemplated.

In some embodiments, the method of manufacturing the medical implant 100 may include securing the occlusive element 120 to the expandable scaffold 110. In some embodiments, at least some of the plurality of anchor members 240 may extend through the occlusive element 120 in the second configuration. In some embodiments, the occlusive element 120 may be disposed along an exterior surface of the expandable scaffold 110. In some embodiments, the occlusive element 120 may cover at least 20% of the expandable scaffold 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 30% of the expandable scaffold 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 40% of the expandable scaffold 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 50% of the expandable scaffold 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 60% of the expandable scaffold 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 70% of the expandable scaffold 110 in the second configuration. Other configurations are also contemplated.

The methods of manufacturing described herein may produce the expandable scaffold 110 with significantly less variability. For example, whereas bending anchor members to form each hook shape individually (e.g., FIG. 3) may have a height tolerance of +/−0.005 inches, forming the hook shape via the cutting step may have a height tolerance of +/−0.001 inches or less. In this example, variability may be reduced by about 5 times, about 8 times, 10 times, etc. In another example, whereas bending anchor members to form each hook shape individually (e.g., FIG. 3) may have an angle tolerance of +/−10 degrees, forming the hook shape via the cutting step may have an angle tolerance of +/−1 degree or less. In this example, variability may be reduced by about 8 times, about 10 times, about 12 times, about 14 times, etc. As a result, incidence of manufacturing scrap may be significantly reduced, thereby improving throughput and reducing the cost of goods. These are only examples, and additional and/or other benefits are also contemplated and/or expected.

The materials that can be used for the various components of the medical implants, systems, and methods of manufacturing disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion refers to the system. However, this is not intended to limit the system, devices, and/or methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein, such as, but not limited to, the expandable scaffold, the plurality of struts, the plurality of anchor members, the occlusive element, etc. and/or elements or components thereof.

In some embodiments, the system and/or components thereof may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material.

Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN®), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL®), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL®), polyamide (for example, DURETHAN® or CRISTAMID®), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), MARLEX® high-density polyethylene, MARLEX® low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID®), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, polyurethane silicone copolymers (for example, Elast-Eon® or ChronoSil®), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments, the system and/or components thereof can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.

Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; platinum; palladium; gold; combinations thereof, or any other suitable material.

In some embodiments, portions or all of the system and/or components thereof may be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique (e.g., ultrasound, etc.) during a medical procedure. This relatively bright image aids a user in determining the location of the system. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the system to achieve the same result.

In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility is imparted into the system. For example, the system and/or components or portions thereof may be made of a material that does not substantially distort the image and create substantial artifacts (e.g., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The system or portions thereof may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R44003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R44035 such as MP35-N® and the like), nitinol, and the like, and others.

In some embodiments, the system may include a textile material. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk. Synthetic biocompatible yarns suitable for use in the present invention include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyls, polymethylacetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes. Moreover, at least one of the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber. Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni—Co—Cr-based alloy. The yarns may further include carbon, glass or ceramic fibers. In some embodiments, the yarns may be made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like. The yarns may be of the multifilament, monofilament, or spun types. The type and denier of the yarn chosen may be selected in a manner which is forms a biocompatible system.

In some embodiments, the system and/or other elements disclosed herein may include and/or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyl ketone)); anti-protein and/or anti-bacterial agents (such as 2-methacryroyloxyethyl phosphorylcholine (MPC) and its polymers or copolymers); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, anti-thrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.

It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The disclosure's scope is, of course, defined in the language in which the appended claims are expressed.

Claims

1. A method of manufacturing a medical implant for occluding a left atrial appendage, comprising:

cutting an expandable scaffold in a first configuration;
wherein the expandable scaffold includes a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts;
forming the expandable scaffold into a second configuration;
wherein forming the expandable scaffold into the second configuration includes bending each anchor member along a bending axis of each anchor member, the bending axis being oriented parallel to a longitudinal axis of a respective strut of the plurality of struts, wherein forming the expandable scaffold into the second configuration further includes preventing the plurality of struts from twisting; and
heat setting the expandable scaffold in the second configuration.

2. The method of claim 1, wherein the expandable scaffold is cut with a laser.

3. The method of claim 1, wherein the first configuration is a radially collapsed configuration and the second configuration is a radially expanded configuration.

4. The method of claim 1, wherein each anchor member extends radially outward from the plurality of struts after bending.

5. The method of claim 1, wherein bending each anchor member further includes preventing the respective strut from rotating about the longitudinal axis of the respective strut as the anchor member is bent.

6. The method of claim 1, wherein the expandable scaffold is formed from a unitary tubular member.

7. The method of claim 6, wherein bending each anchor member includes:

inserting a die into an interior of the expandable scaffold;
positioning the respective strut over a groove formed in the die; and
urging the respective strut into the groove with a punch.

8. The method of claim 1, wherein the expandable scaffold is formed from a flat sheet of material.

9. The method of claim 8, wherein bending each anchor member includes:

positioning the respective strut over a groove formed in a die; and
urging the respective strut into the groove with a punch.

10. The method of claim 8, further comprising forming the flat sheet of material into a tubular member.

11. A method of manufacturing a medical implant for occluding a left atrial appendage, comprising:

cutting an expandable scaffold in a first configuration;
wherein the expandable scaffold including a plurality of struts having ends joined together at intersection points and a plurality of anchor members extending from the plurality of struts such that each anchor member extends from a medial portion of a strut of the plurality of struts;
forming the expandable scaffold into a second configuration;
wherein forming the expandable scaffold into the second configuration includes bending each anchor member along a bending axis of each anchor member, the bending axis being oriented parallel to a longitudinal axis of a respective strut of the plurality of struts, wherein forming the expandable scaffold into the second configuration further includes preventing the plurality of struts from twisting;
heat setting the expandable scaffold in the second configuration; and
securing an occlusive element to the expandable scaffold.

12. The method of claim 11, wherein at least some of the plurality of anchor members extend through the occlusive element in the second configuration.

13. The method of claim 11, wherein the occlusive element is disposed along an exterior surface of the expandable scaffold.

14. The method of claim 13, wherein the occlusive element covers at least 30% of the expandable scaffold in the second configuration.

Referenced Cited
U.S. Patent Documents
178283 June 1876 French
1967318 July 1934 Monahan
3402710 September 1968 Paleschuck
3540431 November 1970 Mobin-Uddin
3557794 January 1971 Van Patten
3638652 February 1972 Kelley
3811449 May 1974 Gravlee et al.
3844302 October 1974 Klein
3874388 April 1975 King et al.
4007743 February 15, 1977 Blake
4108420 August 22, 1978 West et al.
4175545 November 27, 1979 Termanini
4309776 January 12, 1982 Berguer
4341218 July 27, 1982 Ü
4364392 December 21, 1982 Strother et al.
4425908 January 17, 1984 Simon
4545367 October 8, 1985 Tucci
4585000 April 29, 1986 Hershenson
4603693 August 5, 1986 Conta et al.
4611594 September 16, 1986 Grayhack et al.
4619246 October 28, 1986 Molgaard-Nielsen et al.
4638803 January 27, 1987 Rand et al.
4665906 May 19, 1987 Jervis
4681588 July 21, 1987 Ketharanathan et al.
4710192 December 1, 1987 Liotta et al.
4718417 January 12, 1988 Kittrell et al.
4759348 July 26, 1988 Cawood et al.
4781177 November 1, 1988 Lebigot
4793348 December 27, 1988 Palmaz
4827907 May 9, 1989 Tashiro
4832055 May 23, 1989 Palestrant
4873978 October 17, 1989 Ginsburg
4917089 April 17, 1990 Sideris
4921484 May 1, 1990 Hillstead
4960412 October 2, 1990 Fink
4966150 October 30, 1990 Etienne et al.
4998972 March 12, 1991 Chin et al.
5037810 August 6, 1991 Saliba, Jr.
5041090 August 20, 1991 Scheglov et al.
5041093 August 20, 1991 Chu
5042707 August 27, 1991 Taheri
5053009 October 1, 1991 Herzberg
5064435 November 12, 1991 Porter
5071407 December 10, 1991 Termin et al.
5078736 January 7, 1992 Behl
5098440 March 24, 1992 Hillstead
5108418 April 28, 1992 Lefebvre
5108420 April 28, 1992 Marks
5108474 April 28, 1992 Riedy et al.
5116360 May 26, 1992 Pinchuk et al.
5122136 June 16, 1992 Guglielmi et al.
5133733 July 28, 1992 Rasmussen et al.
5171259 December 15, 1992 Inoue
5171383 December 15, 1992 Sagaye et al.
5176692 January 5, 1993 Wilk et al.
5192301 March 9, 1993 Kamiya et al.
5211658 May 18, 1993 Clouse
5234458 August 10, 1993 Metais
5242462 September 7, 1993 El-Nounnou et al.
5256146 October 26, 1993 Ensminger et al.
5258000 November 2, 1993 Gianturco
5258042 November 2, 1993 Mehta
5279539 January 18, 1994 Bohan et al.
5284488 February 8, 1994 Sideris
5304184 April 19, 1994 Hathaway et al.
5306234 April 26, 1994 Johnson
5312341 May 17, 1994 Turi
5329942 July 19, 1994 Gunther et al.
5334217 August 2, 1994 Das
5344439 September 6, 1994 Otten
5350398 September 27, 1994 Pavcnik et al.
5350399 September 27, 1994 Erlebacher et al.
5353784 October 11, 1994 Nady-Mohamed
5366460 November 22, 1994 Eberbach
5366504 November 22, 1994 Andersen et al.
5370657 December 6, 1994 Irie
5375612 December 27, 1994 Cottenceau et al.
5397331 March 14, 1995 Himpens et al.
5397355 March 14, 1995 Marin et al.
5409444 April 25, 1995 Kensey et al.
5417699 May 23, 1995 Klein et al.
5421832 June 6, 1995 Lefebvre
5425744 June 20, 1995 Fagan et al.
5427119 June 27, 1995 Swartz et al.
5433727 July 18, 1995 Sideris
5443454 August 22, 1995 Tanabe et al.
5443478 August 22, 1995 Purdy et al.
5451235 September 19, 1995 Lock et al.
5454365 October 3, 1995 Bonutti
5464408 November 7, 1995 Duc
5469867 November 28, 1995 Schmitt
5490856 February 13, 1996 Person et al.
5497774 March 12, 1996 Swartz et al.
5499975 March 19, 1996 Cope et al.
5499995 March 19, 1996 Teirstein
5522790 June 4, 1996 Voll et al.
5522822 June 4, 1996 Phelps et al.
5522836 June 4, 1996 Palermo
5527322 June 18, 1996 Klein et al.
5527338 June 18, 1996 Purdy
5558093 September 24, 1996 Pomeranz et al.
5558652 September 24, 1996 Henke
5569204 October 29, 1996 Cramer et al.
5591196 January 7, 1997 Marin et al.
5614204 March 25, 1997 Cochrum
5634936 June 3, 1997 Linden et al.
5634942 June 3, 1997 Chevillon et al.
5637097 June 10, 1997 Yoon
5643282 July 1, 1997 Kieturakis
5643292 July 1, 1997 Hart
5649953 July 22, 1997 Lefebvre
5653690 August 5, 1997 Booth et al.
5662671 September 2, 1997 Barbut et al.
5669933 September 23, 1997 Simon et al.
5681345 October 28, 1997 Euteneuer
5681347 October 28, 1997 Cathcart et al.
5683411 November 4, 1997 Kavteladze et al.
5690671 November 25, 1997 McGurk et al.
5693067 December 2, 1997 Purdy
5695525 December 9, 1997 Mulhauser et al.
5700285 December 23, 1997 Myers et al.
5702421 December 30, 1997 Schneidt
5704910 January 6, 1998 Humes
5709224 January 20, 1998 Behl et al.
5709704 January 20, 1998 Nott et al.
5709707 January 20, 1998 Lock et al.
5722400 March 3, 1998 Ockuly et al.
5724975 March 10, 1998 Negus et al.
5725512 March 10, 1998 Swartz et al.
5725552 March 10, 1998 Kotula et al.
5725568 March 10, 1998 Hastings
5733294 March 31, 1998 Forber et al.
5733302 March 31, 1998 Myler et al.
5733325 March 31, 1998 Robinson et al.
5735290 April 7, 1998 Sterman et al.
5749880 May 12, 1998 Banas et al.
5749883 May 12, 1998 Halpern
5749894 May 12, 1998 Engelson
5766219 June 16, 1998 Horton
5766246 June 16, 1998 Mulhauser et al.
5769816 June 23, 1998 Barbut et al.
5776097 July 7, 1998 Massoud
5776162 July 7, 1998 Kleshinski
5782860 July 21, 1998 Epstein et al.
5785679 July 28, 1998 Abolfathi et al.
5800454 September 1, 1998 Jacobsen et al.
5800457 September 1, 1998 Gelbfish
5800512 September 1, 1998 Letnz et al.
5800526 September 1, 1998 Anderson et al.
5807261 September 15, 1998 Benaron et al.
5810874 September 22, 1998 Lefebvre
5814028 September 29, 1998 Swartz et al.
5814029 September 29, 1998 Hassett
5814064 September 29, 1998 Daniel
5820591 October 13, 1998 Thompson et al.
5823198 October 20, 1998 Jones et al.
5830228 November 3, 1998 Knapp et al.
5833673 November 10, 1998 Ockuly et al.
5836913 November 17, 1998 Orth et al.
5836968 November 17, 1998 Simon et al.
5840027 November 24, 1998 Swartz et al.
5843118 December 1, 1998 Sepetka et al.
5846260 December 8, 1998 Maahs
5846261 December 8, 1998 Kotula et al.
5848969 December 15, 1998 Panescu et al.
5849005 December 15, 1998 Garrison et al.
5851232 December 22, 1998 Lois
5853422 December 29, 1998 Huebsch et al.
5855597 January 5, 1999 Jayaraman
5865791 February 2, 1999 Whayne et al.
5865802 February 2, 1999 Yoon et al.
5868702 February 9, 1999 Stevens et al.
5868708 February 9, 1999 Hart et al.
5876367 March 2, 1999 Kaganov et al.
5879296 March 9, 1999 Ockuly et al.
5879366 March 9, 1999 Shaw et al.
5882340 March 16, 1999 Yoon
5885258 March 23, 1999 Sachdeva et al.
5891558 April 6, 1999 Bell et al.
5895399 April 20, 1999 Barbut et al.
5902289 May 11, 1999 Swartz et al.
5904680 May 18, 1999 Kordis et al.
5904703 May 18, 1999 Gilson
5906207 May 25, 1999 Shen
5910154 June 8, 1999 Tsugita et al.
5911734 June 15, 1999 Tsugita et al.
5916236 June 29, 1999 Muij Van de Moer et al.
5925060 July 20, 1999 Forber
5925063 July 20, 1999 Khosravi
5925074 July 20, 1999 Gingras et al.
5925075 July 20, 1999 Myers et al.
5928192 July 27, 1999 Maahs
5928260 July 27, 1999 Chin et al.
5931818 August 3, 1999 Werp et al.
5935145 August 10, 1999 Villar et al.
5935147 August 10, 1999 Kensey et al.
5935148 August 10, 1999 Villar et al.
5941249 August 24, 1999 Maynard
5941896 August 24, 1999 Kerr
5944738 August 31, 1999 Amplatz et al.
5947997 September 7, 1999 Pavcnik et al.
5951589 September 14, 1999 Epstein et al.
5951599 September 14, 1999 McCrory
5954694 September 21, 1999 Sunseri
5954767 September 21, 1999 Pajotin et al.
5957940 September 28, 1999 Tanner et al.
5961545 October 5, 1999 Lentz et al.
5976174 November 2, 1999 Ruiz
5980514 November 9, 1999 Kupiecki et al.
5980555 November 9, 1999 Barbut et al.
5989281 November 23, 1999 Barbut et al.
5993469 November 30, 1999 McKenzie et al.
5993483 November 30, 1999 Gianotti
5997557 December 7, 1999 Barbut et al.
6004280 December 21, 1999 Buck et al.
6004348 December 21, 1999 Banas et al.
6007523 December 28, 1999 Mangosong
6007557 December 28, 1999 Ambrisco et al.
6010517 January 4, 2000 Baccaro
6010522 January 4, 2000 Barbut et al.
6013093 January 11, 2000 Nott et al.
6024751 February 15, 2000 Lovato et al.
6024754 February 15, 2000 Engelson
6024755 February 15, 2000 Addis
6024756 February 15, 2000 Huebsch et al.
6027520 February 22, 2000 Tsugita et al.
6033420 March 7, 2000 Hahnen
6036720 March 14, 2000 Abrams et al.
6042598 March 28, 2000 Tsugita et al.
6048331 April 11, 2000 Tsugita et al.
6051014 April 18, 2000 Jang
6051015 April 18, 2000 Maahs
6056720 May 2, 2000 Morse
6063070 May 16, 2000 Eder
6063113 May 16, 2000 Kavteladze et al.
6066126 May 23, 2000 Li et al.
6068621 May 30, 2000 Balceta et al.
6074357 June 13, 2000 Kaganov et al.
6076012 June 13, 2000 Swanson et al.
6079414 June 27, 2000 Roth
6080182 June 27, 2000 Shaw et al.
6080183 June 27, 2000 Tsugita et al.
6083239 July 4, 2000 Addis
6090084 July 18, 2000 Hassett et al.
6096052 August 1, 2000 Callister et al.
6096053 August 1, 2000 Bates et al.
6110243 August 29, 2000 Wnenchak et al.
6123715 September 26, 2000 Amplatz
6124523 September 26, 2000 Banas et al.
6132438 October 17, 2000 Fleischman et al.
6135991 October 24, 2000 Muni et al.
6136016 October 24, 2000 Barbut et al.
6139527 October 31, 2000 Laufer et al.
6139573 October 31, 2000 Sogard et al.
6152144 November 28, 2000 Lesh et al.
6152946 November 28, 2000 Broome et al.
6156055 December 5, 2000 Ravenscroft
6159195 December 12, 2000 Ha et al.
6161543 December 19, 2000 Cox et al.
6168615 January 2, 2001 Ken et al.
6171329 January 9, 2001 Shaw et al.
6179859 January 30, 2001 Bates et al.
6193739 February 27, 2001 Chevillon et al.
6203531 March 20, 2001 Ockuly et al.
6206907 March 27, 2001 Marino et al.
6214029 April 10, 2001 Thill et al.
6221092 April 24, 2001 Koike et al.
6231561 May 15, 2001 Frazier et al.
6231589 May 15, 2001 Wessman et al.
6235045 May 22, 2001 Barbut et al.
6245012 June 12, 2001 Kleshinski
6251122 June 26, 2001 Tsukernik
6258115 July 10, 2001 Dubrul
6267772 July 31, 2001 Mulhauser et al.
6267776 July 31, 2001 O'Connell
6270490 August 7, 2001 Hahnen
6270530 August 7, 2001 Eldridge et al.
6270902 August 7, 2001 Tedeschi et al.
6277138 August 21, 2001 Levinson et al.
6285898 September 4, 2001 Ben-Haim
6290674 September 18, 2001 Roue et al.
6290708 September 18, 2001 Kugel et al.
6312407 November 6, 2001 Zadno-Azizi et al.
6319251 November 20, 2001 Tu et al.
6328727 December 11, 2001 Frazier et al.
6328755 December 11, 2001 Marshall
6342062 January 29, 2002 Suon et al.
6346116 February 12, 2002 Brooks et al.
6346895 February 12, 2002 Lee et al.
6361545 March 26, 2002 Macoviak et al.
6364895 April 2, 2002 Greenhalgh
6368338 April 9, 2002 Konya et al.
6371971 April 16, 2002 Tsugita et al.
6375670 April 23, 2002 Greenhalgh
6391044 May 21, 2002 Yadav et al.
6398803 June 4, 2002 Layne et al.
6402746 June 11, 2002 Whayne et al.
6402771 June 11, 2002 Palmer et al.
6402779 June 11, 2002 Colone et al.
6419669 July 16, 2002 Frazier et al.
6440152 August 27, 2002 Gainor et al.
6443972 September 3, 2002 Bosma et al.
6447530 September 10, 2002 Ostrovsky et al.
6454775 September 24, 2002 Demarais et al.
6458145 October 1, 2002 Ravenscroft et al.
6464712 October 15, 2002 Epstein et al.
6468291 October 22, 2002 Bates et al.
6468301 October 22, 2002 Amplatz et al.
6485501 November 26, 2002 Green
6488689 December 3, 2002 Kaplan et al.
6511496 January 28, 2003 Huter et al.
6514280 February 4, 2003 Gilson
6517573 February 11, 2003 Pollock et al.
6533782 March 18, 2003 Howell et al.
6547760 April 15, 2003 Samson et al.
6547815 April 15, 2003 Myers
6551303 April 22, 2003 Van Tassel et al.
6551344 April 22, 2003 Thill
6558401 May 6, 2003 Azizi
6558405 May 6, 2003 McInnes
6558414 May 6, 2003 Layne
6562058 May 13, 2003 Seguin et al.
6569184 May 27, 2003 Huter
6569214 May 27, 2003 Williams et al.
6589214 July 8, 2003 McGuckin et al.
6589251 July 8, 2003 Yee et al.
6599308 July 29, 2003 Amplatz
6602271 August 5, 2003 Adams et al.
6623508 September 23, 2003 Shaw et al.
6641564 November 4, 2003 Kraus
6650923 November 18, 2003 Lesh et al.
6652555 November 25, 2003 VanTassel et al.
6652556 November 25, 2003 VanTassel et al.
6666861 December 23, 2003 Grabek
6689150 February 10, 2004 Vantassel et al.
6699260 March 2, 2004 Dubrul et al.
6699276 March 2, 2004 Sogard et al.
6702825 March 9, 2004 Frazier et al.
6712836 March 30, 2004 Berg et al.
6726701 April 27, 2004 Gilson et al.
6730108 May 4, 2004 Van Tassel et al.
6755812 June 29, 2004 Peterson et al.
6827737 December 7, 2004 Hill et al.
6837901 January 4, 2005 Rabkin et al.
6855153 February 15, 2005 Saadat
6911037 June 28, 2005 Gainor et al.
6932838 August 23, 2005 Schwartz et al.
6942653 September 13, 2005 Quinn
6949113 September 27, 2005 Van Tassel et al.
6958061 October 25, 2005 Truckai et al.
6994092 February 7, 2006 van der Burg et al.
7011671 March 14, 2006 Welch
7014645 March 21, 2006 Greene, Jr. et al.
7037321 May 2, 2006 Sachdeva et al.
7044134 May 16, 2006 Khairkhahan et al.
7097651 August 29, 2006 Harrison et al.
7128073 October 31, 2006 van der Burg et al.
7152605 December 26, 2006 Khairkhahan et al.
7169164 January 30, 2007 Borillo et al.
7179275 February 20, 2007 McGuckin, Jr. et al.
7226466 June 5, 2007 Opolski
7303526 December 4, 2007 Sharkey et al.
7323002 January 29, 2008 Johnson et al.
7597704 October 6, 2009 Frazier et al.
7678123 March 16, 2010 Chanduszko
7695425 April 13, 2010 Schweich et al.
7713282 May 11, 2010 Frazier et al.
7722641 May 25, 2010 van der Burg et al.
7727189 June 1, 2010 VanTassel et al.
7735493 June 15, 2010 van der Burg et al.
7748389 July 6, 2010 Salahieh et al.
7780694 August 24, 2010 Palmer et al.
7794472 September 14, 2010 Eidenschink et al.
7799049 September 21, 2010 Ostrovsky et al.
7803171 September 28, 2010 Uflacker
7811300 October 12, 2010 Feller, III et al.
7811314 October 12, 2010 Fierens et al.
7862500 January 4, 2011 Khairkhahan et al.
7927365 April 19, 2011 Fierens et al.
7959645 June 14, 2011 WasDyke et al.
7972359 July 5, 2011 Kreidler
8025495 September 27, 2011 Hardert et al.
8043329 October 25, 2011 Khairkhahan et al.
8052715 November 8, 2011 Quinn et al.
8062282 November 22, 2011 Kolb
8080032 December 20, 2011 van der Burg et al.
8097015 January 17, 2012 Devellian
8173062 May 8, 2012 Durcan
8221384 July 17, 2012 Frazier et al.
8221445 July 17, 2012 van Tassel et al.
8246648 August 21, 2012 Tekulve
8287563 October 16, 2012 Khairkhahan et al.
8323309 December 4, 2012 Khairkhahan et al.
8372143 February 12, 2013 Majercak et al.
8388672 March 5, 2013 Khairkhahan et al.
8491623 July 23, 2013 Vogel et al.
8523897 September 3, 2013 van der Burg et al.
8535343 September 17, 2013 van der Burg et al.
8562509 October 22, 2013 Bates
8663273 March 4, 2014 Khairkhahan et al.
8685055 April 1, 2014 VanTassel et al.
8740931 June 3, 2014 Snow
8834519 September 16, 2014 van der Burg et al.
8845711 September 30, 2014 Miles et al.
8998944 April 7, 2015 Thornton
9034006 May 19, 2015 Quinn et al.
9132000 September 15, 2015 VanTassel et al.
9168043 October 27, 2015 van der Burg et al.
9186152 November 17, 2015 Campbell et al.
9211124 December 15, 2015 Campbell et al.
9445895 September 20, 2016 Kreidler
9554806 January 31, 2017 Larsen et al.
9561037 February 7, 2017 Fogarty et al.
9561097 February 7, 2017 Kim et al.
9629636 April 25, 2017 Fogarty et al.
9700323 July 11, 2017 Clark
9724121 August 8, 2017 Hefer
9730701 August 15, 2017 Tischler et al.
9883936 February 6, 2018 Sutton et al.
9913652 March 13, 2018 Bridgeman et al.
9943299 April 17, 2018 Khairkhahan et al.
9943315 April 17, 2018 Kaplan et al.
10071181 September 11, 2018 Penegor et al.
10076335 September 18, 2018 Zaver et al.
10111645 October 30, 2018 Fearnot et al.
10143458 December 4, 2018 Kreidler
10258454 April 16, 2019 Molgaard-Nielsen et al.
10603020 March 31, 2020 Rudman et al.
10939986 March 9, 2021 Chen et al.
11039822 June 22, 2021 Wang et al.
20010000797 May 3, 2001 Mazzocchi
20010020181 September 6, 2001 Ayne
20010034537 October 25, 2001 Shaw et al.
20010037141 November 1, 2001 Yee et al.
20020022860 February 21, 2002 Borillo et al.
20020035374 March 21, 2002 Borillo et al.
20020045931 April 18, 2002 Sogard et al.
20020062133 May 23, 2002 Gilson et al.
20020082638 June 27, 2002 Porter et al.
20020082675 June 27, 2002 Myers
20020099439 July 25, 2002 Schwartz et al.
20020111647 August 15, 2002 Khairkhahan et al.
20020138094 September 26, 2002 Borillo et al.
20020138097 September 26, 2002 Ostrovsky et al.
20020169475 November 14, 2002 Gainor et al.
20020177855 November 28, 2002 Greene, Jr. et al.
20030017775 January 23, 2003 Dong et al.
20030023262 January 30, 2003 Welch
20030023266 January 30, 2003 Borillo et al.
20030057156 March 27, 2003 Peterson et al.
20030060871 March 27, 2003 Hill et al.
20030120337 June 26, 2003 Van Tassel et al.
20030181942 September 25, 2003 Sutton et al.
20030191526 October 9, 2003 Van Tassel et al.
20030195555 October 16, 2003 Khairkhahan et al.
20030204203 October 30, 2003 Khairkhahan et al.
20030208214 November 6, 2003 Loshakove et al.
20030220667 November 27, 2003 van der Burg et al.
20040034366 February 19, 2004 van der Burg et al.
20040049210 March 11, 2004 VanTassel et al.
20040093012 May 13, 2004 Cully et al.
20040098031 May 20, 2004 van der Burg et al.
20040117004 June 17, 2004 Osborne et al.
20040122467 June 24, 2004 VanTassel et al.
20040127935 July 1, 2004 VanTassel et al.
20040158274 August 12, 2004 WasDyke
20040186486 September 23, 2004 Roue et al.
20040215230 October 28, 2004 Frazier et al.
20040220610 November 4, 2004 Kreidler et al.
20040220682 November 4, 2004 Levine et al.
20040230222 November 18, 2004 van der Burg et al.
20050004652 January 6, 2005 van der Burg et al.
20050015109 January 20, 2005 Lichtenstein
20050038470 February 17, 2005 van der Burg et al.
20050049573 March 3, 2005 Van Tassel et al.
20050070952 March 31, 2005 Devellian
20050113861 May 26, 2005 Corcoran et al.
20050125020 June 9, 2005 Meade et al.
20050177182 August 11, 2005 van der Burg et al.
20050203568 September 15, 2005 Burg et al.
20050283186 December 22, 2005 Berrada et al.
20050288704 December 29, 2005 Cartier et al.
20060015136 January 19, 2006 Besselink
20060030877 February 9, 2006 Martinez et al.
20060052816 March 9, 2006 Bates et al.
20060100658 May 11, 2006 Obana et al.
20060155323 July 13, 2006 Porter et al.
20070066993 March 22, 2007 Kreidler
20070083227 April 12, 2007 van der Burg et al.
20070083230 April 12, 2007 Javois
20070150041 June 28, 2007 Evans et al.
20070156123 July 5, 2007 Moll et al.
20070162048 July 12, 2007 Quinn et al.
20070185471 August 9, 2007 Johnson
20080275536 November 6, 2008 Zarins et al.
20090005803 January 1, 2009 Batiste
20090062841 March 5, 2009 Amplatz et al.
20090099647 April 16, 2009 Glimsdale et al.
20090105747 April 23, 2009 Chanduszko et al.
20090112249 April 30, 2009 Miles et al.
20090149945 June 11, 2009 Pike
20090171386 July 2, 2009 Amplatz et al.
20090254195 October 8, 2009 Khairkhan et al.
20090270972 October 29, 2009 Lane
20090318948 December 24, 2009 Linder et al.
20100004726 January 7, 2010 Hancock et al.
20100016953 January 21, 2010 Sisken et al.
20100049238 February 25, 2010 Simpson
20100106178 April 29, 2010 Obermiller et al.
20100256669 October 7, 2010 Harris et al.
20100324585 December 23, 2010 Miles et al.
20110054515 March 3, 2011 Bridgeman et al.
20110082495 April 7, 2011 Ruiz
20110098525 April 28, 2011 Kermode et al.
20110218566 September 8, 2011 van der Burg et al.
20110301630 December 8, 2011 Hendriksen et al.
20120029553 February 2, 2012 Quinn et al.
20120035643 February 9, 2012 Khairkhahan et al.
20120065662 March 15, 2012 van der Burg et al.
20120125619 May 24, 2012 Wood et al.
20120172654 July 5, 2012 Bates
20120172927 July 5, 2012 Campbell et al.
20120191174 July 26, 2012 Vinluan et al.
20120239077 September 20, 2012 Zaver et al.
20120239083 September 20, 2012 Kreidler
20120245619 September 27, 2012 Guest
20120283585 November 8, 2012 Werneth et al.
20120283773 November 8, 2012 Van Tassel et al.
20120323267 December 20, 2012 Ren
20130006343 January 3, 2013 Kassab et al.
20130012982 January 10, 2013 Khairkhahan et al.
20130018413 January 17, 2013 Oral et al.
20130110154 May 2, 2013 van der Burg et al.
20130131717 May 23, 2013 Glimsdale
20130165735 June 27, 2013 Khairkhahan et al.
20130178889 July 11, 2013 Miles et al.
20130211492 August 15, 2013 Schneider et al.
20130331884 December 12, 2013 Van der Burg et al.
20140005714 January 2, 2014 Quick et al.
20140018841 January 16, 2014 Peiffer et al.
20140039536 February 6, 2014 Cully et al.
20140046360 February 13, 2014 van der Burg et al.
20140081314 March 20, 2014 Zaver et al.
20140100596 April 10, 2014 Rudman et al.
20140142612 May 22, 2014 Li et al.
20140148842 May 29, 2014 Khairkhahan et al.
20140163605 June 12, 2014 VanTassel et al.
20140188157 July 3, 2014 Clark
20140277562 September 18, 2014 Seddon
20140303719 October 9, 2014 Cox et al.
20140336612 November 13, 2014 Frydlewski et al.
20140336699 November 13, 2014 van der Burg et al.
20150005810 January 1, 2015 Center et al.
20150039021 February 5, 2015 Khairkhahan et al.
20150080903 March 19, 2015 Dillard et al.
20150196300 July 16, 2015 Tischler et al.
20150230909 August 20, 2015 Zaver et al.
20150238197 August 27, 2015 Quinn et al.
20150305727 October 29, 2015 Karimov et al.
20150313604 November 5, 2015 Roue et al.
20150313605 November 5, 2015 Griffin
20150327979 November 19, 2015 Quinn et al.
20150374491 December 31, 2015 Kreidler
20160051358 February 25, 2016 Sutton et al.
20160058539 March 3, 2016 VanTassel et al.
20160066922 March 10, 2016 Bridgeman et al.
20160106437 April 21, 2016 van der Burg et al.
20160192942 July 7, 2016 Strauss et al.
20160287259 October 6, 2016 Hanson et al.
20160331382 November 17, 2016 Center et al.
20160374657 December 29, 2016 Kreidler
20170027552 February 2, 2017 Turkington et al.
20170042550 February 16, 2017 Chakraborty et al.
20170056166 March 2, 2017 Ratz et al.
20170100112 April 13, 2017 van der Burg et al.
20170119400 May 4, 2017 Amplatz et al.
20170181751 June 29, 2017 Larsen et al.
20170340336 November 30, 2017 Osypka
20180064446 March 8, 2018 Figulla et al.
20180070950 March 15, 2018 Zaver et al.
20180140412 May 24, 2018 Sutton et al.
20180140413 May 24, 2018 Quinn et al.
20180250014 September 6, 2018 Melanson et al.
20180310925 November 1, 2018 Inouye et al.
20190046213 February 14, 2019 Gong et al.
20190083224 March 21, 2019 Tessmer
20190117367 April 25, 2019 Simpson
20190125362 May 2, 2019 Tischler
20190167242 June 6, 2019 Rowe et al.
20190223883 July 25, 2019 Anderson et al.
20190298380 October 3, 2019 Inouye et al.
20190299011 October 3, 2019 Chu
20200008812 January 9, 2020 Inouye et al.
20200060801 February 27, 2020 Yang
20200060849 February 27, 2020 Inouye et al.
20200178981 June 11, 2020 Anderson et al.
20210015596 January 21, 2021 Nigon
20210059685 March 4, 2021 Groff et al.
Foreign Patent Documents
1399571 February 2003 CN
202143640 February 2012 CN
106859722 June 2017 CN
10201004476 March 2012 DE
1523957 April 2005 EP
1595504 November 2005 EP
2074953 January 2009 EP
2481381 August 2012 EP
2928420 October 2015 EP
3072461 September 2016 EP
3372173 September 2018 EP
3494902 June 2019 EP
2003532457 November 2003 JP
2005324019 November 2005 JP
2007513684 May 2007 JP
2009160402 July 2009 JP
2012501793 January 2012 JP
9313712 July 1993 WO
9504132 February 1995 WO
9522359 August 1995 WO
9601591 January 1996 WO
9640356 December 1996 WO
9721402 June 1997 WO
9726939 July 1997 WO
9728749 August 1997 WO
9735522 October 1997 WO
9802100 January 1998 WO
9817187 April 1998 WO
9822026 May 1998 WO
9823322 June 1998 WO
9827868 July 1998 WO
9905977 February 1999 WO
9907289 February 1999 WO
9908607 February 1999 WO
9923976 May 1999 WO
9925252 May 1999 WO
9930640 June 1999 WO
9944510 September 1999 WO
9959479 November 1999 WO
0001308 January 2000 WO
0016705 March 2000 WO
0027292 May 2000 WO
0035352 June 2000 WO
0053120 September 2000 WO
0067669 November 2000 WO
0108743 February 2001 WO
0115629 March 2001 WO
0121247 March 2001 WO
0126726 April 2001 WO
0130266 May 2001 WO
0130267 May 2001 WO
0130268 May 2001 WO
0170119 September 2001 WO
0215793 February 2002 WO
0224106 March 2002 WO
02071977 September 2002 WO
03007825 January 2003 WO
03008030 January 2003 WO
03032818 April 2003 WO
2004012629 February 2004 WO
2007044536 April 2007 WO
2010024801 March 2010 WO
2010081033 July 2010 WO
2013060855 May 2013 WO
2013159065 October 2013 WO
2014011865 January 2014 WO
2014018907 January 2014 WO
2014078698 May 2014 WO
2014089129 June 2014 WO
2014106239 July 2014 WO
2015164836 October 2015 WO
2016087145 June 2016 WO
2018017935 January 2018 WO
2018187732 October 2018 WO
2019084358 May 2019 WO
2021052486 March 2021 WO
Other references
  • International Search Report and Written Opinion dated Aug. 3, 2004 for International Application No. PCT/US2004/008109.
  • International Search Report and Written Opinion dated Feb. 15, 2000 for International Application No. PCT/US99/26325.
  • International Search Report dated May 20, 2003 for International Application No. PCT/US02/33808.
  • Written Opinion dated Nov. 17, 2003 for International Application No. PCT/US/02/33808.
  • International Search Report and Written Opinion dated Aug. 21, 2018 for International Application No. PCT/US2018/029684.
  • Cragg et al., “A New Percutaneous Vena Cava Filter,” American Journal of Radiology, Sep. 1983, pp. 601-604, vol. 141.
  • Cragg et al., “Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire,” Radiology, Apr. 1983, pp. 261-263, vol. 147, No. 1.
  • Lock et al., “Transcatheter Closure of Atrial Septal Defects.” Circulation, May 1989, pp. 1091-1099, vol. 79, No. 5.
  • Lock et al., “Transcatheter Umbrella Closure of Congenital Heart Defects,” Circulation, Mar. 1987, pp. 593-599, vol. 75, No. 3.
  • Rashkind et al., “Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System,” Circulation, Mar. 1987, pp. 583-592, vol. 75, No. 3.
  • Rosengart et al., “Percutaneous and Minimally Invasive Valve Procedures,” Circulation, Apr. 1, 2008, pp. 1750-1767, vol. 117.
  • Ruttenberg, “Nonsurgical Therapy of Cardiac Disorders,” Pediatric Consult, 1986, Pages not numbered, vol. 5, No. 2.
  • Sugita et al., “Nonsurgical Implantations of a Vascular Ring Prosthesis Using Thermal Shape Memory Ti/Ni Alloy (Nitinol Wire),” Trans. Am. Soc. Artif. Intern. Organs, 1986, pp. 30-34, vol. XXXII.
  • Wessel et al., “Outpatient Closure of the Patent Ductus Arteriousus,” Circulation, 1988, pp. 1068-1071, vol. 77, No. 5.
  • Tung et al., U.S. Appl. No. 61/559,941, filed Nov. 15, 2011.
  • Yue Yu et al., U.S. Appl. No. 61/557,880, filed Dec. 20, 2011.
  • Cline, “File: Fish hooks.jpg,” Wikipedia foundation , Inc., San Francisco, CA, Jun. 2007; p. 1 of 4; available online at http://en.wikipedia.org/wiki/File:Fish_hooks.jpg; last accessed Oct. 5, 2012.
  • International Search Report and Written Opinion dated Apr. 22, 2014 for International Application No. PCT/US2013/078454.
  • Aryana et al., “Incomplete Closure of the Left Atrial Appendage: Implication and Management.” Curr Cardiol Rep., 18(9):82, 2016.
  • Delurgio, “Device-Associated Thrombus and Peri-Device Leak Following Left Atrial Appendage Closure with the Amplatzer Cardiac Plug.” JACC: Cardiovascular Interventions, 10(4): 400-402, 2017.
  • University of Minnesota. Atlas of Human Cardiac Anatomy, Left Atrium. Retrieved from http://www.vhlab.umn.edu/atlas/left-atrium/left-atrial-appendage/index.shtml. Accessed 2017. Downloaded 2019.
  • Saw et al., “Incidence and Clinical Impact of Device-Associated Thrombus and Peri-Device Leak following Left Atrial Appendage Closure with the Amplatzer Cardiac Plug.” JACC: Cardiovascular Intervention. 10(4): 391-399, 2017.
  • Romero et al., “Left Atrial Appendage Closure Devices,” Clinical Medicine Insights: Cardiology, vol. 8, pp. 45-52, 2014.
  • Invitation To Pay Additional Fees And, Where Applicable, Protest Fee, for International Application No. PCT/ US2016/043363, mailed Oct. 13, 2016.
  • International Search Report and Written Opinion dated Oct. 14, 2019 for International Application No. PCT/US2019/047452.
  • International Search Report and Written Opinion dated Oct. 27, 2017 for International Application No. PCT/US2017/048150.
  • International Search Report and Written Opinion dated Jan. 21, 2019 for International Application No. PCT/US2018/051953.
  • International Search Report and Written Opinion dated Oct. 13, 2016 for International Application No. PCT/US2016/043363.
  • International Search Report and Written Opinion dated Mar. 17, 2020, for International Application No. PCT/US2019/065243.
  • International Search Report and Written Opinion dated Sep. 9, 2019 for International Application No. PCT/US2019/033698.
  • Blackshear et al; “Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients with Atrial Fibrillation”, Ann. Thoracic Surgery, pp. 755-759, 1996.
  • Lindsay, “Obliteration of the Left Atrial Appendage: A Concept Worth Testing”, Ann. Thoracic Surgery, 1996.
  • Invitation To Pay Additional Fees dated Feb. 22, 2019 for International Application No. PCT/US2018/066163.
  • International Search Report and Written Opinion dated Oct. 23, 2020 for International Application No. PCT/US2020/042192.
  • International Search Report and Written Opinion dated Aug. 25, 2023 for International Application No. PCT/US2023/024824.
  • International Search Report and Written Opinion dated Feb. 23, 2023 for International Application No. PCT/US2022/049080.
  • International Search Report and Written Opinion dated Dec. 6, 2022 for International Application No. PCT/US2022/042696.
  • LabCE. https://www.labce.com/spg579126_red_blood_cell_rbc_size_variation.aspx. “Red Blood Cell (RBC) Size Variation”, 2019.
Patent History
Patent number: 12714431
Type: Grant
Filed: Jun 8, 2023
Date of Patent: Aug 25, 2026
Patent Publication Number: 20230397912
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Inventors: Josh Tillman (New Brighton, MN), Joshua Mark Inouye (Brooklyn Park, MN)
Primary Examiner: Sarang Afzali
Assistant Examiner: Darrell C Ford
Application Number: 18/207,455
Classifications
Current U.S. Class: Mechanically Securing Parts Together By Reshaping Joint Portion Only (264/249)
International Classification: A61B 17/12 (20060101); A61B 17/00 (20060101);